RRC ID 63256
著者 Sagara M, Miyamoto S, Itoh S, Soda Y, Tani K.
タイトル Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
ジャーナル Anticancer Res
Abstract BACKGROUND/AIM:Breast cancer is the most common cancer in women worldwide, and triple-negative breast cancer (TNBC) is highly refractory to current standard therapies. Oncolytic virotherapy has recently gathered attention as a new treatment candidate for refractory cancers.
MATERIALS AND METHODS:We previously developed a new Coxsackievirus B3 (CVB3) virotherapy targeting lung cancers, and demonstrated that miRNA target sequence insertion into CVB3 reduced its pathogenicity, retaining its original oncolytic activity. In this study, we examined the oncolytic effects of CVB3 against breast cancer cells including TNBC cells.
RESULTS:CVB3 infection killed breast cancer cells in a time- and titer-dependent manner, and induced apoptosis. Nude mice transplanted with human TNBC cells were successfully treated with both CVB3-WT and CVB3-HP. Importantly, mice treated with CVB3-HP showed very few adverse events.
CONCLUSION:CVB3-HP is a strong oncolytic virus candidate for breast cancer, including TNBC, due to its remarkable oncolytic efficacy and improved safety profile.
巻・号 41(1)
ページ 81-89
公開日 2021-1-1
DOI 10.21873/anticanres.14753
PII 41/1/81
PMID 33419801
MeSH Animals Breast Neoplasms / genetics* Breast Neoplasms / pathology Breast Neoplasms / therapy Cell Line, Tumor Cells, Cultured Cytopathogenic Effect, Viral Disease Models, Animal Enterovirus B, Human / genetics* Female Flow Cytometry Gene Expression Genetic Therapy* / methods Genetic Vectors / administration & dosage Genetic Vectors / adverse effects Genetic Vectors / genetics* Humans Immunohistochemistry Mice Oncolytic Virotherapy* / methods Oncolytic Viruses / genetics* Treatment Outcome Xenograft Model Antitumor Assays
IF 1.994
リソース情報
ヒト・動物細胞 MDA-MB-453(RCB1192) MCF7(RCB1904)